Рациональная антигипертензивная терапия: уменьшение риска сердечнососудистых осложнений - не только результат снижения артериального давления (по результатам исследования LIFE)
https://doi.org/10.18705/1607-419X-2003-9-1-5-8
Аннотация
Список литературы
1. Konnel W. В. Fiftyyears of Framingham Study contributions to understanding hypertension.J Hum Hypertens 2000; 14: 83-90.
2. Veterans Administration Cooperative Study Group on Antibypertettsive Agents. Effectsoftreatmenton morbidity in hypertension.JAMA 1970; 213 (7): 1143-52.
3. Collins R, Peto R, MacMabon S et al. Blood pressure, stroke, and coronary heart disease. Lancet 1990; 335:827-38.
4. Рекомендации no профилактике, диагностике пленению артериальной гипертензии. Артер. гипертен, 2002 (Примечание).
5. Harisson L., Linвbolm L.H. Ekorm T et al. Randomised trial of old and new anti-hypertensive drugs in eldery patients. Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension - 2 study. Lancet 1999; 354: 1751-6.
6. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blokers on cardiovascular morbidity and mortality in hypertension, The Nordic Diltiazem (NORDlL) Study. Lancet 2000; 356:359-65-
7. Staessen J.A., Wang J.-G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15-
8. Dahlot B, Devereux RD, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359' 995-1003.
9. Dablot B, Keller SE, Makris L et al. Effecacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertension 1995; 8:578-83. 10.1999
10. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-83-
11. Lindbolm L.H., Ibsen H., Dahlot B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartanlntervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359:1004-10.
12. Kjeldsen S.E., Dahlot B., Devereux R.B. et al. Effectsof Losartan on Cardiovascular Morbidity and Mortality in patients with Isolated Systolic Hypertension and left ventricular hypertrophy. JAMA 2002; 288:1491
Рецензия
Для цитирования:
Чазова И.Е. Рациональная антигипертензивная терапия: уменьшение риска сердечнососудистых осложнений - не только результат снижения артериального давления (по результатам исследования LIFE). Артериальная гипертензия. 2003;9(1):5-8. https://doi.org/10.18705/1607-419X-2003-9-1-5-8
For citation:
Chazova I.Ye. Rational antihypertensive therapy: a reduced risk for cardiovascular events is not only the result of blood pressure lowering: results of the LIFE study. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2003;9(1):5-8. (In Russ.) https://doi.org/10.18705/1607-419X-2003-9-1-5-8